INS and type 2 diabetes mellitus: GLP‐1 receptor (GLP‐1R) activation leads to enhanced satiety, weight loss, decreased glucose production in the liver, and enhanced insulin sensitivity in skeletal muscle; GLP‐1R agonists are currently in clinical use for the treatment of T2D 7.